myelodysplastic syndrome
FDA Lifts Partial Clinical Holds for Some Gilead Trials
Gilead's Phase III ENHANCE trials of magrolimab combinations are clear to move forward, while earlier stage trials in blood cancers remain in limbo.Â
Large Study Identifies Potential Therapeutic Targets for MDS Patients who Fail Initial Treatment
Premium
The study showed that the stem cell profiles of MDS patients could be used to stratify them into two subgroups associated with differential response to Venclexta.
Precigen Validating Non-Viral, Next-Day CAR T-Cell Manufacturing Platform for Use at Place of Care
Premium
The firm is using a proprietary system to manufacture autologous CAR T-cell therapies, including for solid tumors, at the hospitals where patients are treated.
FDA Puts Partial Hold on Gilead's Magrolimab-Chemo Combination Trials in AML, MDS
In pausing trials of Gilead's anti-CD47 agent plus azacitidine, the agency cited concerns about an imbalance of adverse events between the studies' treatment arms.
Rarecells, Columbia University to Study Liquid Biopsy Test for Early Detection of AML
The study, slated to begin next year, will evaluate Rarecells' ISET-AML test in patients with myelodysplastic syndrome.